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There is only one big risk you should avoid at all costs, and that is 
the risk of doing nothing
J. Daemen
becomes even more challenging, especially when there is 
concomitant haemodynamic instability and/or concurrent 
infusion with vasoactive substances. Subsequently, when 
the operator is convinced that a particular non-culprit lesion 
has to be treated, the following dilemma already pops up. A 
decision has to be made on direct versus staged treatment 
or postponing the potential intervention awaiting residual 
symptoms or objective evidence of ischaemia. Compar-
ing ‘ad hoc’ multivessel versus infarct-related artery-only 
revascularisation in the setting of STEMI and multivessel 
disease is therefore an oversimplification of the actual clini-
cal problem.
Clear answers can only be provided by large dedicated 
randomised controlled trials with adequate power and pre-
defined guiding on post-procedural care, patient informa-
tion and treatment timing of repeat interventions. The lack 
of these clear guidelines, typically applied in randomised 
controlled trials, is exactly the reason why observational 
and mostly retrospective studies fail to provide convincing 
answers to our clinical dilemma. The latter is demonstrated 
by clear differences in the cohorts of patients in individual 
observational studies. Treatment groups differ in age, dia-
betes, presence of haemodynamic instability and disease 
complexity. Not even to speak about the huge imbalance 
in numbers of patients per group; multivessel PCI was per-
formed in only 13.9 % of the patients versus 86.1 % who 
received infarct artery only treatment as demonstrated by 
Rasoul and colleagues. Pooling data makes things even more 
complicated because this potpourri of studies is character-
ised by differential inclusion criteria, follow-up durations, 
endpoint definitions and most importantly the definition of 
multivessel versus infarct-related artery-only PCI. There-
fore, if the ‘raw material’ is flawed, the conclusions of sys-
tematic reviews and meta-analyses cannot be trusted [7].
This issue of the Netherland Heart Journal presents the 
meta-analysis of Rasoul et al. [1] in which they question 
the optimal treatment strategy for patients presenting with 
ST-segment elevation myocardial infarction (STEMI) and 
multivessel coronary artery disease, an extremely relevant 
question to those who are regularly confronted with STEMI 
patients. The study queues up in line with a large number of 
studies and meta-analyses on the same topic published in 
the past 10 years. Unfortunately, their results are conflicting, 
which is not surprising given the differential study designs 
and potpourri of confounders in the research question.
Patients who are diagnosed with multivessel disease fair 
worse than those with single-vessel disease as reflected by 
higher morbidity and mortality rates, a fact that holds irre-
spective of the patient’s clinical status at presentation [2–4]. 
The latter triggered the discussion on how to achieve the 
most optimal, and complete, revascularisation strategy by 
either multivessel percutaneous coronary revascularisa-
tion (PCI) or coronary artery bypass graft surgery in which 
besides multiple clinical factors angiographic characteristics 
such as lesion complexity and haemodynamic consequence 
as determined by fractional flow reserve (FFR) measure-
ments come into play [5, 6]. The latter proved to be of par-
ticular importance because the capacity of even the most 
experienced interventional cardiologists in assessing lesion 
severity and haemodynamic consequences proved to be lim-
ited. In the setting of primary PCI, assessing lesion severity 
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Preventive Angioplasty in Acute Myocardial Infarction 
(PRAMI) was the first randomised controlled trial showing 
a benefit for complete revascularisation, demonstrating a 
65 % reduction in major adverse cardiac events over a mean 
follow-up of 23 months for total versus culprit-only PCI 
[8]. The PRAMI was followed by the recently presented 
the Complete Versus Lesion-only PRimary PCI Trial (CvL-
PRIT) study, a prospective open-label, multicentre UK trial 
including 296 patients (excluding shock patients). The study 
confirmed that major adverse cardiac events rates were sig-
nificantly lower in those who received multivessel revas-
cularisation, driven by a reduction in all-cause mortality, 
myocardial infarction, heart failure and repeat PCI. How-
ever, in both studies, staging the intended multivessel revas-
cularisation was allowed. In CvLPRIT, more than 27 % of 
the patients included received non-culprit artery treatment 
several days after the primary PCI. Although these two 
important clinical trials shed new light on our research ques-
tion, they also triggered a similar amount of debate. Both 
trials were open-label, and patients were aware of the pres-
ence of residual stenosis which might have triggered repeat 
events. As mentioned earlier in the text, staged PCI was dis-
couraged, but still happened in a considerable number of 
patients. No data on left ventricular function were available, 
and finally, most studies concerning revascularisation have 
defined significant stenosis as a narrowing of at least 70 %, 
while in PRAMI, lesions with a stenosis of more than 50 % 
were eligible for revascularisation.
Besides the wealth of studies on the topic, one can 
only conclude that a simple yes or no answer to the ques-
tion whether to perform ad hoc multivessel PCI in STEMI 
patients with multivessel disease simply does not exist today 
and probably will not even exist in the future. Therefore, the 
best we can do is trust on our own personal judgment of the 
individual patient, keeping in mind the following facts that 
we do know:
 ● Assessing non-culprit lesions in the setting of a primary 
PCI is challenging because lesion severity can often be 
overestimated.
 ● Staging allows haemodynamic lesion assessment using 
fractional flow reserve, which proved to result in avoid-
ing unnecessary interventions, saving costs and improv-
ing hard clinical endpoints.
 ● Stenting in a prothrombotic inflammatory milieu is not 
preferred.
 ● Unforeseen peri-procedural complications are always at 
risk.
 ● Direct or staged multivessel PCI decreases the need for 
further hospitalisations and subsequent interventions that 
might be cost saving.
 ● Individual non-culprit lesion complexity, procedure 
time, contrast volume and haemodynamic status of the 
patient should be taken into account at all times.
 ● In case of complex multivessel disease, surgical manage-
ment during the acute and subacute phase proved to be 
associated with excellent 30-day and 1-year survival [9].
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